Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Treasury Shares: 2014-2024

Historic Treasury Shares for Amphastar Pharmaceuticals (AMPH) over the last 11 years, with Dec 2024 value amounting to $332.7 million.

  • Amphastar Pharmaceuticals' Treasury Shares rose 33.33% to $387.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $387.7 million, marking a year-over-year increase of 33.33%. This contributed to the annual value of $332.7 million for FY2024, which is 34.47% up from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its Treasury Shares stood at $332.7 million for FY2024, which was up 34.47% from $247.4 million recorded in FY2023.
  • Amphastar Pharmaceuticals' Treasury Shares' 5-year high stood at $1.4 million during FY2020, with a 5-year trough of -$13.2 million in FY2024.
  • Moreover, its 3-year median value for Treasury Shares was -$11.3 million (2023), whereas its average is -$11.5 million.
  • Data for Amphastar Pharmaceuticals' Treasury Shares shows a peak YoY soared of 34.47% (in 2024) over the last 5 years.
  • Over the past 5 years, Amphastar Pharmaceuticals' Treasury Shares (Yearly) stood at $121.8 million in 2020, then increased by 23.53% to $150.5 million in 2021, then increased by 25.95% to $189.5 million in 2022, then soared by 30.55% to $247.4 million in 2023, then surged by 34.47% to $332.7 million in 2024.